Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics (NQ: ABEO )

1.910 USD -0.070 (-3.54%)
Official Closing Price Updated: 7:58 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Abeona Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
Investor Conference Call on Tuesday, March 27th at 10:00 am ET 
From GlobeNewswire News Releases
Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
Company’s 4th Gene Therapy Program to Receive Rare Pediatric Disease Designation, enabling Priority Review Voucher 
From GlobeNewswire News Releases
Technical Perspectives on Biotech Stocks -- 22nd Century, Abeona Therapeutics, Advaxis, and Adverum Biotechnologies
From PR Newswire
New Research Coverage Highlights Western Alliance, Matson, Vail Resorts, Abeona Therapeutics, Under Armour, and AGNC Investment — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Western Alliance... 
From GlobeNewswire News Releases
Abeona Therapeutics Announces Upcoming Conference Participation
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today... 
From GlobeNewswire News Releases
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced... 
From GlobeNewswire News Releases
Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today... 
From GlobeNewswire News Releases
Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today reported... 
From GlobeNewswire News Releases
Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today... 
From GlobeNewswire News Releases
Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced... 
From GlobeNewswire News Releases
Biotech Stocks' Research Reports Released on 22nd Century, Abeona Therapeutics, Acasti Pharma, and Aeterna Zentaris
From PR Newswire
NASDAQ:ABEO Investor Alert: Investigation over Possible Wrongdoing at Abeona Therapeutics Inc
San Diego, CA -- (SBWIRE) -- 01/09/2018 -- An investigation was announced for investors of Abeona Therapeutics Inc (NASDAQ:ABEO) shares over potential securities laws violations in connection with... 
From SBWire - Latest Press Releases
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of... 
From PR Newswire
Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today that... 
From GlobeNewswire News Releases
Biotech Stocks' Research Reports Released on PhaseRx, Abeona Therapeutics, Imprimis Pharma, and Jaguar Health
In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on PZRX, ABEO, IMMY, and JAGX which is a click away at... 
From PR Newswire
Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced financial results for... 
From GlobeNewswire News Releases
Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare diseases, announced today that... 
From GlobeNewswire News Releases
Biotech Stocks on Investors' Radar -- Synthetic Biologics, 22nd Century, Abeona Therapeutics, and Aeterna Zentaris
From PR Newswire
Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, today announced the... 
From GlobeNewswire News Releases
Positive Developments From Clinical Studies and FDA Approvals Pushing Biotech Stocks to New Highs
MarketNewsUpdates.com News Commentary 
From PR Newswire
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, today announced the... 
From GlobeNewswire News Releases
Abeona Therapeutics Announces Public Offering of Common Stock
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, today announced that... 
From GlobeNewswire News Releases
Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today a... 
From GlobeNewswire News Releases
Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that two... 
From GlobeNewswire News Releases
Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced one year... 
From GlobeNewswire News Releases
Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today the... 
From GlobeNewswire News Releases
Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today an... 
From GlobeNewswire News Releases
Abeona Therapeutics Announces Upcoming Conference Participation
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, today announced the... 
From GlobeNewswire News Releases
Technical Snapshots for These Biotech Stocks -- ImmunoCellular Therapeutics, Protalix BioTherapeutics, Synthetic Biologics, and Abeona Therapeutics
From PR Newswire
Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa
Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the U.S.... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.